地高辛片致男性乳腺增生1 例分析

doi:10.19803/j.1672-8629.20210979

中国药物警戒 ›› 2023, Vol. 20 ›› Issue (3): 346-347.
DOI: 10.19803/j.1672-8629.20210979

地高辛片致男性乳腺增生1 例分析

欧阳荧^1,2, 钟常歆^1,2, 夏春华², 聂俊刚¹, 周颖^1,*

¹南昌大学第一附属医院药学部,江西南昌 330006;
²南昌大学药学院,江西南昌330006

收稿日期:2021-11-09 出版日期:2023-03-15 发布日期:2023-03-17
通讯作者: ^* 周颖,女,博士,副主任药师,临床药学。E-mail: zyyiva@163.com
作者简介:欧阳荧,女,在读硕士,临床药学。
基金资助:
国家自然科学基金资助项目（81903724）

One case of breast hyperplasia caused by digoxin tablets

OUYANG Ying^1,2, ZHONG Changxin^1,2, XIA Chunhua², NIE Jungang¹, ZHOU Ying^1,*

¹Department of Pharmacy, the First Affiliated Hospital of Nanchang University, Nanchang Jiangxi 330006, China;
²College of Pharmacy, Nanchang University, Nanchang Jiangxi 330006, China

Received:2021-11-09 Online:2023-03-15 Published:2023-03-17

摘要/Abstract

摘要： 目的探讨地高辛片导致乳腺增生病例,为临床预防及处理其不良反应提供参考。方法分析1例服用地高辛片导致乳腺增生患者的治疗过程,探讨地高辛片致乳腺增生的机制并排除其他药物的可能性。结果患者服用地高辛后双侧乳腺增生,停用该药并继续服用其他药物治疗1月后,乳房不适减轻。结论地高辛片致乳腺增生或与洋地黄类药物的类雌激素作用有关,用药期间应定期做乳房检查,同时也需防范地高辛片其他严重的不良反应。

关键词: 地高辛, 乳腺增生, 乳房发育, 雌激素, 雄激素, 药品不良反应

Abstract: Objective To study one case of breast hyperplasia induced by digoxin tablets in order to provide reference for clinical prevention and treatment of related adverse reactions. Methods The process of treating one patient who had developed breast hyperplasia after taking digoxin tablets was analyzed. The mechanism by which digoxin tablets caused breast hyperplasia was investigated and the possibility of involvement of other drugs was ruled out. Results The patient had bilateral breast hyperplasia after taking digoxin. After the drug was discontinued and other medications were used for one month, breast discomfort decreased. Conclusion Breast hyperplasia caused by digoxin tablets may be related to the estrogen-like effect of digitalis drugs, so regular breast examination is required during medication. It is also important to guard against other serious adverse reactions caused by digoxin tablets.

Key words: digoxin, breast hyperplasia, breast development, estrogen, androgen, adverse drug reactions

中图分类号:

R994.11

欧阳荧, 钟常歆, 夏春华, 聂俊刚, 周颖. 地高辛片致男性乳腺增生1 例分析[J]. 中国药物警戒, 2023, 20(3): 346-347.

OUYANG Ying, ZHONG Changxin, XIA Chunhua, NIE Jungang, ZHOU Ying. One case of breast hyperplasia caused by digoxin tablets[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 346-347.

参考文献

[1] Heart Failure Group of Cardiology Branch of Chinese Medical Association, Heart Failure Professional Committee of Chinese Medical Doctor Association, Editorial Board of Chinese Journal of Cardiovascular Diseases. Chinese Heart Failure Diagnosis and Treatment Guidelines 2018[J]. Chinese Journal of Heart Failure and Cardiomyopathy(中华心力衰竭和心肌病杂志), 2018, 2(4): 196-225.
[2] CHEN C, YOU L.Diagnosis and treatment of digoxin in patients with chronic heart failure[J]. Health Vision(健康大视野), 2018(11): 200.
[3] FU HY.Monitoring results of digoxin blood concentration and analysis of adverse reactions in 219 cases[J]. Laboratory Medicine and Clinic(检验医学与临床), 2016, 13(z1): 57-59.
[4] XU CF.The effect of levosimendan and digoxin in the treatment of chronic heart failure and its adverse reactions[J]. Contemporary Medicine(当代医学), 2021, 27(25): 32-34.
[5] MACLEOD-GLOVER N, MINK M, YAREMA M, et al.Digoxin toxicity Case for retiring its use in elderly patients?[J]. Canadian Family Physician, 2016, 62(3): 223-228.
[6] LIN Y, MU DL.Advances in surgical treatment of gynecomastia[J]. Chinese Journal of Aesthetic Plastic Surgery(中国美容整形外科杂志), 2021, 32(6): 344-347.
[7] GAO Z, JING CF.Analysis of the causes of mammary gland hyperplasia in a male patient with heart failure by clinical pharmacists[J]. Journal of Pharmacy Practice(药学实践杂志), 2019, 37(5): 470-472.
[8] COOPEY SB, KARTAL K, LI C, et al.Atypical ductal hyperplasia in men with gynecomastia: What is their breast cancer risk?[J]. Breast Cancer Research and Treatment, 2019, 175(1): 1-4.
[9] KANAKIS G A, NORDKAP L, BANG A K, et al.EAA clinical practice guidelines-gynecomastia evaluation and management[J]. Andrology, 2019, 7(6): 778-793.
[10] BOWMAN JD, KIM H, BUSTAMANTE JJ.Drug-induced gynecomastia[J]. Pharmacotherapy, 2012, 32(12): 1123-1140.
[11] DEEPINDER F, BRAUNSTEIN G D.Drug-induced gynecomastia: an evidence-based review[J]. Expert Opin Drug Saf, 2012, 11(5): 779-795.
[12] LI L, LI Q, WANG JH, et al.Analysis of 23 cases of digitalis overdose related to Qili Qiangxin capsules[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2015, 12(6): 357-359, 362.
[13] PENG HL, GE CQ, HE ZH, et al.Two cases of gynecomastia induced by digoxin[J]. Chinese Journal of Gerontology(中华老年医学杂志), 1999, 18(6): 374.
[14] MOHAMMAD MK, KASIJAGADEESH M, KUMARASWAMY RC.Spironolactone/ Digoxin-induced gynecomastia(a comparative case study)[J]. World Journal of Pharmaceutical Research(世界药物研究杂志), 2014, 3(6): 1014-1018.
[15] WANG Y, WANG PF, LIU GD, et al.A case of male breast hyperplasia caused by spironolactone tablets[J]. Chinese Pharmacist(中国药师), 2019, 22(7): 1315.
[16] TIAN LX, JIA XX.Analysis of a case of gynecomastia caused by spironolactone[J]. Chinese Health Nutrition(中国保健营养), 2016, 26(14): 147-148.
[17] Measures for the reporting and monitoring of adverse drug reactions[J]. Communiqué of the Ministry of Health of the People’s Republic of China, 2011, (6): 1-10.
[18] Chinese Pharmacological Society.Proceedings of the 2011 National Medical Academic Papers Exchange Conference(2011年全国医药学术论坛交流会暨临床药学与药学服务研究进展培训班论文集)[C]. Taiyuan: 2011.
[19] THIRUCHELVAM P, WALKER J N, ROSE K, et al.Gynaecomastia[J]. BMj-British Medical Journal, 2016, 354: i4833.

地高辛片致男性乳腺增生1 例分析

One case of breast hyperplasia caused by digoxin tablets

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[9]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[10]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[11]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[12]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[13]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[14]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[15]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.